Literature DB >> 23519385

Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage.

Jennifer L Aron1, Robert Gosselin, Stephan Moll, Charles F Arkin, Simon Mantha.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 23519385     DOI： 10.1007/s11239-013-0913-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  10 in total

1.  Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding.

Authors:  Theodore E Warkentin; Peter Margetts; Stuart J Connolly; Andre Lamy; Chris Ricci; John W Eikelboom
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

2.  The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: mechanistic implications for clinical medicine.

Authors:  Patrick K Davis; Harsha Musunuru; Mark Walsh; Raman Mitra; Victoria Ploplis; Francis J Castellino
Journal:  Thromb Haemost       Date:  2012-07-10       Impact factor: 5.249

3.  Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants.

Authors:  M M Samama; L Le Flem; C Guinet; G Gerotziafas; F Depasse
Journal:  J Thromb Haemost       Date:  2007-12       Impact factor: 5.824

4.  Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.

Authors:  Raphael Marlu; Enkelejda Hodaj; Adeline Paris; Pierre Albaladejo; Jean Luc Cracowski; Jean Luc Crackowski; Gilles Pernod
Journal:  Thromb Haemost       Date:  2012-05-25       Impact factor: 5.249

Review 5.  Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

Authors:  Joanne van Ryn; Joachim Stangier; Sebastian Haertter; Karl-Heinz Liesenfeld; Wolfgang Wienen; Martin Feuring; Andreas Clemens
Journal:  Thromb Haemost       Date:  2010-03-29       Impact factor: 5.249

6.  Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.

Authors:  Jonathan Douxfils; François Mullier; Séverine Robert; Christian Chatelain; Bernard Chatelain; Jean-Michel Dogné
Journal:  Thromb Haemost       Date:  2012-03-22       Impact factor: 5.249

7.  Neurosurgical complications of direct thrombin inhibitors--catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran.

Authors:  Sarah T Garber; Walavan Sivakumar; Richard H Schmidt
Journal:  J Neurosurg       Date:  2012-03-06       Impact factor: 5.115

8.  A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor.

Authors:  Tami Livnat; Uri Martinowitz; Ariella Zivelin; Dardik Rima; Gili Kenet
Journal:  Thromb Haemost       Date:  2011-01-12       Impact factor: 5.249

9.  Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?

Authors:  Brian Dale; John W Eikelboom; Jeffrey I Weitz; Ed Young; Jeremy S Paikin; Michiel Coppens; Richard P Whitlock; Stuart J Connolly; Jeffrey S Ginsberg; Jack Hirsh
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

10.  Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro.

Authors:  Yiming Xu; Weizhen Wu; Liangsu Wang; Madhu Chintala; Andrew S Plump; Martin L Ogletree; Zhu Chen
Journal:  Blood Coagul Fibrinolysis       Date:  2013-04       Impact factor: 1.276
  10 in total
  2 in total

Review 1.  Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review.

Authors:  Boris Arbit; Jonathan C Hsu
Journal:  Clin Cardiol       Date:  2015-07-14       Impact factor: 2.882

Review 2.  Monitoring of hematological and hemostatic parameters in neurocritical care patients.

Authors:  Andrew M Naidech; Monisha A Kumar
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.